{"id":23688,"date":"2015-06-02T11:46:30","date_gmt":"2015-06-02T09:46:30","guid":{"rendered":"http:\/\/localhost\/chu-poitiers\/service-de-cancerologie-biologique\/"},"modified":"2015-06-02T11:46:30","modified_gmt":"2015-06-02T09:46:30","slug":"service-de-cancerologie-biologique","status":"publish","type":"page","link":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/","title":{"rendered":"Service de canc\u00e9rologie biologique"},"content":{"rendered":"<h2 style=\"text-align: center;\"><a href=\"https:\/\/www.chu-poitiers.fr\/specialites\/cancerologie-biologique\/\">Acc\u00e9der au site du service de canc\u00e9rologie biologique.<\/a><\/h2>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/www.chu-poitiers.fr\/pole-biologie-pharmacie-sante-publique-biologie-medicale\/\" target=\"_blank\" rel=\"noopener noreferrer\">Biologie m\u00e9dicale<\/a> &#8211; <a href=\"?page_id=309\" target=\"_self\" rel=\"noopener noreferrer\">Pharmacie<\/a>\u00a0&#8211; <a title=\"Service de g\u00e9n\u00e9tique\" href=\"www.chu-poitiers.fr\/?page_id=5064\">Service de g\u00e9n\u00e9tique<\/a>\u00a0&#8211;\u00a0<span style=\"color: #e74c3c;\">Service de canc\u00e9rologie biologique<\/span><\/p>\n<div class=\"tab-me-wrapper\"><ul class=\"tab-me-tabs\"><li class=\"active cols3\" class=\"cols3\"><a href=\"javascript:void(0)\" rel=\"tab1161\"><span>Pr\u00e9sentation des activit\u00e9s<\/span><\/a><\/li><li class=\"cols3\"><a href=\"javascript:void(0)\" rel=\"tab1422\"><span>\u00c9quipe m\u00e9dicale et param\u00e9dicale<\/span><\/a><\/li><li class=\"cols3\"><a href=\"javascript:void(0)\" rel=\"tab1346\"><span>Enseignement - recherche<\/span><\/a><\/li><\/ul><!-- .tab-me-tabs --><div class=\"tab-me-content-wrapper\"><div class=\"tab-me-tab-content\" id=\"tab1161\" ><h2>SERVICE DE CANC\u00c9ROLOGIE BIOLOGIQUE<\/h2>\n<p>Chef de service : <span style=\"color: #003366;\"><strong>Pr Lucie KARAYAN-TAPON<\/strong><\/span><br \/>\nCadre de sant\u00e9\u00a0: <span style=\"color: #003366;\"><strong>Florence MAR\u00c9CHAL<\/strong><\/span><\/p>\n<h3>Diagnostic et suivi<\/h3>\n<p>Le laboratoire de canc\u00e9rologie biologique est le si\u00e8ge de la plateforme r\u00e9gionale de g\u00e9n\u00e9tique mol\u00e9culaire des cancers Poitou-Charentes, labellis\u00e9e par la DHOS et l\u2019Institut national du cancer\u00a0(Inca). La mise en \u00e9vidence de l\u2019enjeu que constitue aujourd\u2019hui la m\u00e9decine personnalis\u00e9, a conduit <strong>l\u2019Institut national du cancer<\/strong>\u00a0en 2006, au constat que des plates-formes destin\u00e9es \u00e0 \u00e9tablir la carte d\u2019identit\u00e9 des tumeurs doivent se d\u00e9velopper au sein de tous les p\u00f4les r\u00e9gionaux de canc\u00e9rologie. (<strong>Mesure 21<\/strong> : garantir un acc\u00e8s \u00e9gal aux traitements et aux innovations. Action 21.2 : d\u00e9velopper les plateformes de g\u00e9n\u00e9tique mol\u00e9culaire des cancers et l\u2019acc\u00e8s aux tests mol\u00e9culaires). Notre plateforme a \u00e9t\u00e9 labellis\u00e9e d\u00e8s 2006 et couvre un bassin de population de 1 745 123 habitants (recensement 2008).<\/p>\n<p>La m\u00e9decine personnalis\u00e9e est la capacit\u00e9, pour un patient donn\u00e9, de r\u00e9aliser un profil mol\u00e9culaire (recherche de mutations, de translocations, de transcrits de fusion\u2026) de sa tumeur afin de mettre en \u00e9vidence le ou les anomalie(s) responsable(s) de l\u2019activation d\u2019une voie de signalisation essentielle pour la survie de la tumeur et de proposer une th\u00e9rapeutique ciblant l\u2019anomalie en question. Le choix th\u00e9rapeutique sera donc fond\u00e9 sur la mise en \u00e9vidence de l\u2019anomalie ou biomarqueur.<\/p>\n<p>Le laboratoire est compos\u00e9e de deux unit\u00e9s m\u00e9dicales (UM)\u00a0<u>:<\/u><\/p>\n<p><strong>Unit\u00e9 m\u00e9dicale d\u2019oncologie mol\u00e9culaire (Pr L. Karayan-Tapon).<\/strong><\/p>\n<p><strong>Unit\u00e9 m\u00e9dicale d\u2019h\u00e9matologie mol\u00e9culaire (Dr J.-C. Chomel).<\/strong><\/p>\n<p>Ces deux UM assurent le diagnostic et le suivi mol\u00e9culaire des tumeurs solides et h\u00e9mopathies malignes pris en charge au CHU de Poitiers et dans la r\u00e9gion Poitou-Charentes. Le but final, quelque soit le type de cancer (tumeurs solides ou h\u00e9mopathies malignes), \u00e9tant de pouvoir stratifier les patients d\u00e8s le diagnostic afin que le traitement le plus appropri\u00e9 puisse \u00eatre propos\u00e9, suivre l\u2019efficacit\u00e9 du traitement au niveau mol\u00e9culaire et pr\u00e9dire le plus pr\u00e9cocement possible une rechute de la maladie.<\/p>\n<p><strong>Marqueurs pr\u00e9dictifs d\u00e9terminant l\u2019acc\u00e8s \u00e0 une th\u00e9rapie cibl\u00e9e\u00a0: m<\/strong>utations d\u2019EGFR, mutations de RAS (KRAS, NRAS), mutations de BRAF, mutations de KIT\/PDGFRa, mutations de PI3K, mutations d\u2019HER2, amplification de HER2, translocations de ALK, translocations ROS1, d\u00e9tection des r\u00e9arrangements BCR-ABL, PML-RARa, FIP1L1-PDGFRa, mutations BCR-ABL, mutation JAK2, insertions\/d\u00e9l\u00e9tion de CALR.<\/p>\n<p><strong>Marqueurs orientant le processus diagnostique\u00a0: <\/strong>Instabilit\u00e9 des microsatellites, m\u00e9thylation du promoteur de MLH1, pertes d\u2019h\u00e9t\u00e9rozygotie 1p\/19q, mutations IDH1\/2, d\u00e9tection des r\u00e9arrangements CBFB-MYH11, AML1-ETO,TEL-AML1, E2A-PBX, SIL-TAL, MLL, IgH-Bcl1 et IgH-Bcl2, mise en \u00e9vidence de la r\u00e9p\u00e9tition en tandem de FLT3, mutations de NPM1, expression de la cycline D1<\/p>\n<p><strong>Marqueurs de suivi\u00a0: <\/strong>M\u00e9thylation de MGMT, quantification des ARNm BCR-ABL, PML-RARa, CBFB-MYH11, AML1-ETO, WT1, NPM1 mut\u00e9s, TEL-AML1, E2A-PBX, SIL-TAL, all\u00e8les JAK2 V617F, MLL<\/p>\n<p><strong>Activit\u00e9\u00a0:<\/strong> environ 40 000 actes, 4,2M de B\/BHN par an.<\/p>\n<h3>Technologies \/ m\u00e9thodes utilis\u00e9es au laboratoire<\/h3>\n<p>Les technologies suivantes ont \u00e9t\u00e9 d\u00e9velopp\u00e9es au laboratoire\u00a0:<\/p>\n<ul>\n<li>Extraction des acides nucl\u00e9iques (ADN g\u00e9nomique et ARN totaux) \u00e0 partir de diff\u00e9rents pr\u00e9l\u00e8vements biologiques (sang, moelle osseuse, ganglions, tumeur, liquides pleuraux), de coupes en paraffine et de tissu congel\u00e9.<\/li>\n<li>Contr\u00f4le et dosage des acides nucl\u00e9iques.<\/li>\n<li>R\u00e9verse transcription.<\/li>\n<li>Recherche de r\u00e9arrangements mol\u00e9culaires (transcrits de fusion) par RT-PCR en point final et en temps r\u00e9el.<\/li>\n<li>Recherche de mutations ponctuelles connues par PCR RFLP, PCR all\u00e8le sp\u00e9cifique, PCR en temps r\u00e9el all\u00e8le sp\u00e9cifique.<\/li>\n<li>Recherche de mutations par DGGE.<\/li>\n<li>Caract\u00e9risation de mutations par pyros\u00e9quen\u00e7age.<\/li>\n<li>Caract\u00e9risation de mutations par s\u00e9quen\u00e7age direct double brin.<\/li>\n<li>Dosage des all\u00e8les mut\u00e9s par PCR quantitative avec pr\u00e9sence d\u2019une gamme standard de plasmides.<\/li>\n<li>Dosage des transcrits de fusion par RT-PCR quantitative avec pr\u00e9sence d\u2019une gamme standard de plasmides (\u00e9valuation de la maladie r\u00e9siduelle).<\/li>\n<li>FISH sur tissu inclus en paraffine pour la cytog\u00e9n\u00e9tique des tumeurs solides<\/li>\n<li>Le s\u00e9quen\u00e7age \u00e0 haut d\u00e9bit (miSeq\/Illumina).<\/li>\n<\/ul>\n<h3>Projet P\u00e9dagogique<\/h3>\n<p>Un des enjeux de la canc\u00e9rologie actuelle est l\u2019importance de la connaissance de la biologie du cancer dans son exercice. La mise en place d\u2019une m\u00e9decine personnalis\u00e9e en canc\u00e9rologie n\u00e9cessite d\u2019une part une \u00ab\u00a0vraie\u00a0\u00bb connaissance des voies de la canc\u00e9rog\u00e9n\u00e8se d\u2019une mani\u00e8re g\u00e9n\u00e9rale, mais n\u00e9cessite aussi la connaissance de la biologie canc\u00e9reuse d\u2019un organe donn\u00e9 avec la mise en exergue des g\u00e8nes \u00ab\u00a0driver\u00a0\u00bb et les perturbations fonctionnelles qui d\u00e9coulent de cette addiction oncog\u00e9nique. La prise ne charge des patients atteints de cancer se fait dans la pluridisciplinarit\u00e9\u00a0; l\u2019enseignement de la biologie du cancer n\u00e9cessite cette approche pluridisciplinaire.<\/p>\n<p>Il est important, dans le contexte actuel de l\u2019\u00e9volution de la biologie du cancer, de former des professionnels ayant la comp\u00e9tence de Biologie en Canc\u00e9rologie, plus particuli\u00e8rement ceux qui auront en charge la validation biologique des examens de g\u00e9n\u00e9tique somatique \u00e0 vis\u00e9e sanitaires. Ces analyses sont actuellement r\u00e9alis\u00e9es sur les pi\u00e8ces d\u2019ex\u00e9r\u00e8se ou \u00e9chantillons de biopsie pour les tumeurs solides, ainsi que dans le sang, la moelle osseuse, les ganglions lymphatiques pour les h\u00e9mopathies malignes. Dans les ann\u00e9es prochaines ces tests mol\u00e9culaires (diagnostique, pronostique, th\u00e9ranostique) \u00e9volueront et auront comme objet vraisemblablement les liquides biologiques (ADN\/ARN circulant, cellules canc\u00e9reuses circulants..).<\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p>Participation \u00e0 l\u2019activit\u00e9 de groupes coop\u00e9rateurs\u00a0: Canc\u00e9rop\u00f4le GO, INCa, ANOCEF<\/p>\n<p>CNU de rattachement\u00a0: Canc\u00e9rologie \u2013Radioth\u00e9rapie 4702<\/p>\n<p><strong><a href=\"https:\/\/www.chu-poitiers.fr\/eBooks\/ChuMag63\/index.html#\/26\/\" target=\"_blank\" rel=\"noopener noreferrer\"><img decoding=\"async\" class=\"alignleft wp-image-7589\" src=\"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg\" alt=\"chumag63_traitement-cancer\" width=\"150\" height=\"208\" srcset=\"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg 285w, https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer-216x300.jpg 216w, https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer-130x181.jpg 130w\" sizes=\"(max-width: 150px) 100vw, 150px\" \/><\/a>Vers un traitement cibl\u00e9 du cancer.<br \/>\n<\/strong>CHU Magazine n\u00b063 \u2013 d\u00e9cembre 2011<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p><\/div><div class=\"tab-me-tab-content\" id=\"tab1422\" style=\"display:none\"><h2 align=\"left\">SERVICE DE CANC\u00c9ROLOGIE BIOLOGIQUE<\/h2>\n<p>Responsable m\u00e9diale : <span style=\"color: #003366;\"><strong>Pr Lucie KARAYAN-TAPON<\/strong><\/span><br \/>\nCadre de sant\u00e9 :<span style=\"color: #003366;\"><strong> Florence MAR\u00c9CHAL<\/strong><\/span><br \/>\nSecr\u00e9tariat : T\u00e9l 05 49 4(43 746) &#8211; Fax 05 49 4(44 095)<\/p>\n<p>Personnel m\u00e9dical :<\/p>\n<p>Dr Jean-Claude CHOMEL (praticien hospitalier) (h\u00e9matologie mol\u00e9culaire)<br \/>\nDr Claire VILLALVA-GREGOIRE (praticien hospitalier) (oncologie biologique)<\/p><\/div><div class=\"tab-me-tab-content\" id=\"tab1346\" style=\"display:none\"><h2><strong>INSERM U1084<\/strong> Laboratoire de neurosciences exp\u00e9rimentales et cliniques<\/h2>\n<p><strong>Th\u00e8mes d\u00e9velopp\u00e9 au sein de l\u2019unit\u00e9 Inserm U1084<\/strong> Laboratoire de neurosciences exp\u00e9rimentales et cliniques (LNEC) (Pr M. JABER).<\/p>\n<p><strong>Les tumeurs gliales<\/strong> : \u00e9tude et caract\u00e9risation des cellules souches de gliomes en terme de sensibilit\u00e9 aux th\u00e9rapies nouvelles et conventionnelles, radiosensibilit\u00e9 intrins\u00e8que, signalisation et g\u00e8nes impliqu\u00e9s dans leur migration et relation avec le microenvironnement. Etude g\u00e9nomique des gliomes de bas grade (collaborations avec les services de neurochirurgie, neurologie,\u00a0 oncologie m\u00e9dicale, radioth\u00e9rapie, anatomie pathologique).<\/p>\n<p><strong>Activit\u00e9 de recherche translationnelle hors gliomes<\/strong><\/p>\n<p>Concernant toutes les autres pathologies canc\u00e9reuses \u00e9tudi\u00e9es au laboratoire comme les tumeurs colorectales, ad\u00e9nocarcinomes pulmonaires et m\u00e9lanomes, des observations faites chez les patients lors des analyses de routine peuvent \u00eatre approfondies, impliquant une \u00e9troite coop\u00e9ration entre biologistes et cliniciens. Des mises au point et comparaisons de techniques de g\u00e9n\u00e9tique mol\u00e9culaire peuvent \u00e9galement donner lieu \u00e0 des travaux de recherche.<\/p>\n<p><strong>Mod\u00e8le LMC<\/strong>\u00a0: \u00e9tude du ph\u00e9nom\u00e8ne persistance de cellules souches leuc\u00e9miques, \u00e9tude du ph\u00e9nom\u00e8ne d\u2019instabilit\u00e9 g\u00e9n\u00e9tique associ\u00e9 \u00e0 la niche h\u00e9matopo\u00ef\u00e9tique, analyse de la niche leuc\u00e9mique et \u00e9tude du ph\u00e9nom\u00e8ne de s\u00e9nescence (en relation avec la persistance et la r\u00e9sistance des cellules souches leuc\u00e9miques aux inhibiteurs de tyrosine kinase).<\/p>\n<p>Les projets de recherche sont soutenus par la Ligue contre le cancer, l\u2019association Sport et collection et l\u2019association En avant la vie.<\/p>\n<p><strong>Principales publications \u00a0des trois derni\u00e8re ann\u00e9es<\/strong><\/p>\n<p><strong>Balbous A<\/strong>, Renoux B, <strong>Cortes U<\/strong>, Milin S, <strong>Guilloteau K,<\/strong> Legigan T, <strong>Rivet P<\/strong>, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, <strong>Karayan-Tapon L<\/strong> (2014). <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25053823\">Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.<\/a> Mol Cancer Ther 13(9):2159-69.<\/p>\n<p><strong>Karayan-Tapon L<\/strong>, <strong>Cortes U, Rivet P<\/strong>, Jermidi C, Vassal G, Wager M, Taillandier L. <a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24999209\">Lack of GOPC-ROS1 (FIG-ROS1) rearrangement in adult human gliomas.<\/a> Eur J Cancer. 2014 50(13):2364-6.<\/p>\n<p><strong>Balbous A, Cortes U, Guilloteau K, Villalva C,<\/strong> Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, <strong>Chomel JC, Karayan-Tapon L<\/strong> (2014). A mesenchymal glioma stem cell profile is related to clinical outcome.Oncogenesis. 17;3:<\/p>\n<p><strong>Chomel JC<\/strong>, Aggoune D, <strong>Sorel N<\/strong>, Turhan AG (2014). Leuc\u00e9mie my\u00e9lo\u00efde chronique &#8211; Un mod\u00e8le de dialogue entre la cellule souche leuc\u00e9mique et la niche h\u00e9matopo\u00ef\u00e9tique. <em>Medecine Sciences (Paris)<\/em>;30 : 452-461.<\/p>\n<p>Levescot A, Flamant S, Basbous S, Jacomet F, F\u00e9raud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, <strong>Chomel JC<\/strong>, Turhan A, Guilhot F, Girard JP, Gombert JM, Herbelin A (2014).\u00a0 BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34+ progenitors from chronic myeloid leukemia patients. <em>Cancer Res<\/em>;74 : 2669-2676.<\/p>\n<p>Aggoune D, Tosca L, <strong>Sorel N<\/strong>, Bonnet ML, Dkhissi F, Tachdjian G, Bennaceur-Griscelli A, <strong>Chomel JC<\/strong>, Turhan AG (2014). Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. <em>Oncoscience<\/em>;1 : 57-68.<\/p>\n<p>Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, R\u00e9a D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, <strong>Chomel JC<\/strong>, Turhan A, Guilhot J, Guilhot F, Mahon FX (2014). Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. <em>J Clin Oncol<\/em>;32 : 424-430.<\/p>\n<p>Etcheverry A, Aubry M, Idbaih A, Vauleon E, Marie Y, Menei P, Boniface R, Figarella-Branger D,<strong> Karayan-Tapon L<\/strong>, Quillien V, Sanson M, de Tayrac M, Delattre JY, Mosser J.\u00a0 (2014). DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.PLoS One. 18;9(9):e104455.<\/p>\n<p><strong>Villalva\u00a0C.<\/strong>, Duranton-Tanneur V., <strong>Guilloteau K<\/strong>., Burel-Vandenbos F., Wager M., Doyen J., Levillain P., Fontaine D., Blons H., Pedeutour F., <strong>Karayan-Tapon L.<\/strong> (2013). EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients. <em>Cancer Med<\/em>\u00a0;2\u00a0:296-304.<\/p>\n<p>Tougeron D., <strong>Cortes U<\/strong>., Ferru A., <strong>Villalva C<\/strong>., Silvain C., Tourani J.M., Levillain P., <strong>Karayan-Tapon L<\/strong>. (2013). Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol\u00a0;72\u00a0:397-403.<\/p>\n<p>Tougeron D., Lecomte T., Pag\u00e8s J.C., <strong>Villalva C.<\/strong>, Collin C., Ferru A., Tourani J.M., Silvain C., Levillain P., <strong>Karayan-Tapon L<\/strong>. (2013). Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol\u00a0;24\u00a0:1267-1273.<\/p>\n<p>Casetti, L., Martin-Lanneree, S., Najjar, I., Plo, I., Auge, S., Roy, L., <strong>Chomel, J.-C<\/strong>., Lauret, E., Turhan, A.G. and Dusanter-Fourt, I. (2013). Differential Contributions of STAT5A and STAT5B to Stress Protection and Tyrosine Kinase Inhibitor Resistance of Chronic Myeloid Leukemia Stem\/Progenitor Cells. <em>Cancer Res<\/em>; 73: 2052-2058.<\/p>\n<p><strong>Chomel J.C., Sorel N.,<\/strong> Guilhot J., Guilhot F. and Turhan A.G. (2012). BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia. <em>Blood; <\/em>119:2964-2965.<\/p>\n<p><strong>Villalva C<\/strong>., Cortes U., Wager M., Tourani J.M., <strong>Rivet P., Marquant C.<\/strong>, Martin S., Turhan A.G., <strong>Karayan-Tapon L<\/strong>. (2012). O6-Methylguanine-Methyltransferase (MGMT) Promoter Methylation Status in Glioma Stem-Like Cells is Correlated to Temozolomide Sensitivity Under Differentiation-Promoting Conditions. Int J Mol Sci\u00a0;13\u00a0:6983-6994<\/p>\n<p>&nbsp;<\/p><\/div><\/div><\/div><!-- .tabs-wrapper -->\n","protected":false},"excerpt":{"rendered":"<p>Acc\u00e9der au site du service de canc\u00e9rologie biologique. &nbsp; Biologie m\u00e9dicale &#8211; Pharmacie\u00a0&#8211; Service de g\u00e9n\u00e9tique\u00a0&#8211;\u00a0Service\u2026","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-23688","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Service de canc\u00e9rologie biologique - Site du CHU de Poitiers<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Service de canc\u00e9rologie biologique - Site du CHU de Poitiers\" \/>\n<meta property=\"og:description\" content=\"Acc\u00e9der au site du service de canc\u00e9rologie biologique. &nbsp; Biologie m\u00e9dicale &#8211; Pharmacie\u00a0&#8211; Service de g\u00e9n\u00e9tique\u00a0&#8211;\u00a0Service de canc\u00e9rologie biologique\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/\" \/>\n<meta property=\"og:site_name\" content=\"Site du CHU de Poitiers\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/\",\"name\":\"Service de canc\u00e9rologie biologique - Site du CHU de Poitiers\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/wp-content\\\/uploads\\\/2014\\\/09\\\/chumag63_traitement-cancer.jpg\",\"datePublished\":\"2015-06-02T09:46:30+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/en\\\/service-de-cancerologie-biologique\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/wp-content\\\/uploads\\\/2014\\\/09\\\/chumag63_traitement-cancer.jpg\",\"contentUrl\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/wp-content\\\/uploads\\\/2014\\\/09\\\/chumag63_traitement-cancer.jpg\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#website\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/\",\"name\":\"Site du CHU de Poitiers\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#organization\",\"name\":\"CHU de Poitiers\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Logo-Horizontal-CHU-Poitiers_Couleurs.png\",\"contentUrl\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Logo-Horizontal-CHU-Poitiers_Couleurs.png\",\"width\":2245,\"height\":1064,\"caption\":\"CHU de Poitiers\"},\"image\":{\"@id\":\"https:\\\/\\\/www.chu-poitiers.fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Service de canc\u00e9rologie biologique - Site du CHU de Poitiers","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/","og_locale":"en_US","og_type":"article","og_title":"Service de canc\u00e9rologie biologique - Site du CHU de Poitiers","og_description":"Acc\u00e9der au site du service de canc\u00e9rologie biologique. &nbsp; Biologie m\u00e9dicale &#8211; Pharmacie\u00a0&#8211; Service de g\u00e9n\u00e9tique\u00a0&#8211;\u00a0Service de canc\u00e9rologie biologique","og_url":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/","og_site_name":"Site du CHU de Poitiers","og_image":[{"url":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/","url":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/","name":"Service de canc\u00e9rologie biologique - Site du CHU de Poitiers","isPartOf":{"@id":"https:\/\/www.chu-poitiers.fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/#primaryimage"},"image":{"@id":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/#primaryimage"},"thumbnailUrl":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg","datePublished":"2015-06-02T09:46:30+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chu-poitiers.fr\/en\/service-de-cancerologie-biologique\/#primaryimage","url":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg","contentUrl":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2014\/09\/chumag63_traitement-cancer.jpg"},{"@type":"WebSite","@id":"https:\/\/www.chu-poitiers.fr\/#website","url":"https:\/\/www.chu-poitiers.fr\/","name":"Site du CHU de Poitiers","description":"","publisher":{"@id":"https:\/\/www.chu-poitiers.fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chu-poitiers.fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.chu-poitiers.fr\/#organization","name":"CHU de Poitiers","url":"https:\/\/www.chu-poitiers.fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chu-poitiers.fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2022\/02\/Logo-Horizontal-CHU-Poitiers_Couleurs.png","contentUrl":"https:\/\/www.chu-poitiers.fr\/wp-content\/uploads\/2022\/02\/Logo-Horizontal-CHU-Poitiers_Couleurs.png","width":2245,"height":1064,"caption":"CHU de Poitiers"},"image":{"@id":"https:\/\/www.chu-poitiers.fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/pages\/23688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/comments?post=23688"}],"version-history":[{"count":0,"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/pages\/23688\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.chu-poitiers.fr\/en\/wp-json\/wp\/v2\/media?parent=23688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}